Products
Mapatumumab Biosimilar Monoclonal Antibody (DR4) for Research
Cat No.: GMP-Bios-INN-905
Anti-TNFRSF10A/TRAIL-R1 therapeutic antibody (Pre-made Mapatumumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody undergoing clinical trials for the treatment of cancer.[1] It targets TRAIL-R1, also known as DR4, which is expressed on the surface of many tumor cell types.[2]
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-905-1mg | 1mg | 3090 |
| GMP-Bios-INN-905-10mg | 10mg | |
| GMP-Bios-INN-905-100mg | 100mg | |
| GMP-Bios-INN-905-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Mapatumumab Biosimilar, Whole Mab, Anti-TNFRSF10A/TRAIL-R1 Antibody: Anti-APO2/CD261/DR4/TRAILR-1/TRAILR1 therapeutic antibody |
| INN Name | Mapatumumab |
| Target | TNFRSF10A/TRAIL-R1 |
| Format | Whole mAb |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - nd |
| VD LC | IgG1 - nd |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Cambridge Antibody Technology (Cambridge UK) / Human Genome Sciences Inc. (HGSI) (Rockville MD USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | Cambridge Antibody Technology (CAT) human antibody phage display library |
